CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ultivue, a life science company developing reagent-driven strategies for
high-performance biological imaging in situ, today announced expanded
capabilities of its proprietary InSituPlex® DNA-barcoding and
staining technology. InSituPlex® now supports a higher level
of multiplexed detection and quantification of markers in tissue samples
while retaining all the benefits of the company’s UltiMapper™ assays.
“We are delighted to introduce our 9-color/8-marker whole-slide, single
staining step multiplexing assay which provides exceptional data quality
and throughput, with sample-to-analysis workflow achieved in a single
workday, using instrumentation and software solutions currently found in
most immunohistochemistry laboratories,” said Philippe Mourere,
Ultivue’s Senior Vice President of Commercial Operations. Data
illustrating the assay workflow and performance will be presented in the
poster sessions on Saturday, November 10th by Dr. Gourab Chatterjee,
Scientist at Ultivue.
“Ultivue continues executing its strategic plan by delivering
breakthrough innovations that fuel our portfolios of Products and
Services, making tissue multiplexing a realized assay from exploratory
discovery to translational and clinical research,” added Mourere.
Ultivue’s scientific team is also presenting 5 high impact posters at
the upcoming SITC Annual Meeting, at the Walter E. Washington Convention
Center in Washington, D.C., from November 7 to 11, 2018. Data will
showcase the performance of two new UltiMapper™ I/O research kits for
the detection and quantitation of Antigen Presenting Cells (APC), and
the characterization of T-cell activation (T-act) in tumor tissue
samples. Ultivue’s APC kit (CD11c, CD20, CD68/CD163, MHC II) and T-act
kit (CD3, GranzymeB, Ki67, CK/Sox10) synergistically complement the
existing UltiMapper™ I/O PD-L1 and PD-1 kits for the holistic
immuno-profiling of the tumor microenvironment.
“We will also present new data on the expansion of the automated
UltiMapper™ protocol and workflows, as well as data illustrating
differentiated PD-L1 expression levels on multiple cell types,” said
Karan Sharma, Product Manager at Ultivue. “Additionally, InSituPlex®
technology improvements, and robust assay verification data will be
presented as evidence of exceptional assay performance and
reproducibility in a wide range of FPPE tissue samples.”
Ultivue’s team will be available to engage with the SITC community and
discuss your current and future research projects at booth #625,
throughout the duration of the conference.
Our scientists will be presenting at the following poster numbers and
Friday, November 9, 12:45 PM-2:15 PM & 6:30 PM-8 PM
• P39: PD-L1 expression on tumor versus antigen presenting cells
investigated with multiplexed IHC using UltiMapper™ I/O assays.
• P627: From staining to analysis: fully automated workflow for
multiplexed immuno-profiling in FFPE tumor samples using UltiMapper™
Saturday, November 10, 12:20 PM-1:50 PM & 7 PM-8:30 PM
• P38: Highly multiplex spatial immuno-profiling in FFPE tumor tissue
with InSituPlex® technology.
• P40: Intra-assay and inter-assay assessment of reproducibility and
quantification of UltiMapper I/O PD-1 and PD-L1 immuno-oncology panels
for tissue multiplexing.
• P654: T-cell Profiling in cancer tissue with multiplexed IHC using
UltiMapper™ I/O assays.
Multiplexed biomarker assays in tissue for personalized medicine
research and digital pathology.
By developing a single set of novel, proprietary reagents used both for
biomarker discovery (higher content, low throughput) and translational
use (lower content, high throughput), Ultivue is connecting the insights
gained from research directly into the pathology lab. Ultivue’s
UltiMapper™ multiplexed assays applied to tissue biopsy samples enable
simultaneous quantitation of multiple biomarkers with sub-cellular
spatial resolution and fit completely within traditional IHC workflows.
Translational and clinical researchers leverage UltiMapper™ assays to
elucidate complex biology and demonstrate their clinical utility as
precision medicine research tools. Ultivue is expanding its UltiMapper™
assay product portfolio and menu of contract research services to
provide a comprehensive set of personalized medicine solutions for
oncology research and focus in other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com
Louis Levy, +1-617-945-2662